Want to see HK:0455 full AI Analyst Report?
Tianda Pharmaceuticals Ltd. (0455) AI Stock Analysis
Top Page
Tianda Pharmaceuticals Ltd.
(HKEX:0455)
The score is primarily constrained by persistent losses, declining revenue, weak cash conversion, and negative technical momentum. Controlled leverage and oversold indicators provide only limited support, while the negative P/E and absence of dividend yield further weaken the outlook.
Tianda Pharmaceuticals Ltd. (0455) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 191.35M
- Dividend Yield
- ―
- Average Volume (3M)
- 272.13K
- Price to Earnings (P/E)
- -2.7
- Beta (1Y)
- 0.82
- Revenue Growth
- 12.89%
- EPS Growth
- -2.56%
- Country
- Hong Kong
- Employees
- 613
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Tianda Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September 201...
Tianda Pharmaceuticals Ltd. Financial Statement Overview
Summary
Weak profitability and cash generation outweigh the relatively controlled leverage. The income statement score is 28 due to worsening losses and declining revenue; balance sheet stability scores 65; cash flow scores 42 because operating cash flow is weak and free cash flow deteriorated.
Income Statement
28NegativeBalance Sheet
65PositiveCash Flow
42Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 186.31M | 322.94M | 329.94M | 532.09M | 546.69M | 509.96M |
| Gross Profit | 76.73M | 133.31M | 152.02M | 255.53M | 251.52M | 241.22M |
| EBITDA | -746.00K | -15.44M | -15.92M | 15.66M | -19.89M | -5.14M |
| Net Income | -36.76M | -70.00M | -61.37M | -24.16M | -54.64M | -19.77M |
Balance Sheet | ||||||
| Total Assets | 747.83M | 747.83M | 765.02M | 917.29M | 1.09B | 1.16B |
| Cash, Cash Equivalents and Short-Term Investments | 64.81M | 64.81M | 85.69M | 162.44M | 343.44M | 348.58M |
| Total Debt | 132.66M | 132.66M | 127.44M | 113.60M | 141.05M | 160.43M |
| Total Liabilities | 291.46M | 291.46M | 259.36M | 325.35M | 434.23M | 375.08M |
| Stockholders Equity | 456.64M | 456.64M | 505.84M | 592.07M | 627.83M | 756.75M |
Cash Flow | ||||||
| Free Cash Flow | -14.19M | 2.80M | -52.30M | -116.04M | 54.73M | -61.98M |
| Operating Cash Flow | -10.29M | 14.42M | -9.70M | -49.76M | 79.11M | -8.23M |
| Investing Cash Flow | -5.53M | -20.38M | -31.77M | -69.10M | -12.20M | 86.35M |
| Financing Cash Flow | -4.20M | -15.31M | -30.65M | -57.39M | -28.98M | -1.29M |
Tianda Pharmaceuticals Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0455, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 28.41 is Positive, neither overbought nor oversold. The STOCH value of 30.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0455.
Tianda Pharmaceuticals Ltd. Peers Comparison
Overall Rating
HK:023977Outperform
HK:234859Neutral
HK:089758.6Neutral
HK:085854Neutral- HK:045544Neutral
HK:149842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 77Outperform | HKD 774.43M | 7.76 | 13.59% | 7.44% | 10.63% | 39.44% |
| HK:2348 | 59Neutral | HKD 1.39B | 5.12 | 6.78% | 6.85% | 6.55% | 36.62% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0858 | 54Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:0455 | 44Neutral | HKD 191.35M | -2.73 | -14.55% | ― | 12.89% | -2.56% |
| HK:1498 | 42Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0455 | Tianda Pharmaceuticals Ltd. | 0.09 | -0.05 | -34.07% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% | |
| HK:2348 | Dawnrays Pharmaceutical Holdings Ltd. | 0.92 | -0.20 | -17.86% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.48 | 0.25 | 11.09% |
Tianda Pharmaceuticals Ltd. Corporate Events
Tianda Pharmaceuticals Narrows Comprehensive Loss Despite Higher Interim Revenue
Tianda Pharmaceuticals reported interim revenue of HK$164.2 million for the six months ended 30 June 2026, up from HK$136.6 million a year earlier, driven by higher sales despite increased cost of sales and operating expenses. The company’s gro...
Tianda Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results
Tianda Pharmaceuticals Limited has scheduled a board meeting for 10 August 2026 to approve the interim results for the six months ended 30 June 2026, signaling the imminent release of its mid-year financial performance. The announcement indicates rou...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026